Analysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)
Stifel Maintains Equillium(EQ.US) With Buy Rating, Cuts Target Price to $2
Equillium Cut to Hold From Buy by Jones Trading
Equillium Analyst Ratings
JonesTrading Downgrades Equillium(EQ.US) to Hold Rating
Equillium Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Equillium, Maintains $5 Price Target
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
H.C. Wainwright Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $5
Analysts' Top Healthcare Picks: AC Immune SA (ACIU), Equillium (EQ)
Equillium Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Equillium, Maintains $5 Price Target
HC Wainwright & Co. : The Equillium (EQ.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
Equillium Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Equillium, Maintains $5 Price Target
Buy Rating Affirmed for Equillium on Milestones and Financial Prospects
Buy Rating on Equillium as Promising Trials and Financial Stability Signal Upside Potential
Buy Rating Affirmed for Equillium on Strong Itolizumab Data and Promising EQ101 Phase 2 Prospects
Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides
Equillium Analyst Ratings